Such “(R)-2HG-restoring” mechanisms of resistance have been described in IDH-mutant leukemia patients treated with ivosidenib or enasidenib and in IDH-mutant cholangiocarcinomas59–64. This evidence concerns the gene IDH1 and leukemia.